Samy Hamdouche
Seeking Alpha
Los Angeles, CA, United States
Contact Samy
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Samy:
How I Beat The Market In 2017
My biotech strategy comprises applying a value investing principles to outcomes with high volatility. My portfolio based on this strategy returned 114% in 2017. → Read More
2 Methods I Use To Get Data On Biotech Companies Before The Market
Hedge funds frequently trade on information that is public but not readily accessible to the average investor. This semi-public information is a major source of → Read More
Zogenix: The Proof Is In The Publications
ZGNX's lead asset, ZX-008, is a low-dose of fenfluramine, a drug that has a controversial history as part of the drug combination fen-phen. ZX-008 has demonstra → Read More
The Wild World Of Biotech Insider Trading
Legal restrictions on insider trading have been evolving continuously for the last 100 years and are fraught with grey areas. Traders today are able to exploit → Read More
Foamix Pharmaceuticals: Persistence Pays Off
FOMX lost 50% of its market cap after a near miss in Phase 3 trial of FMX-101 in moderate-to-severe acne. FMX-101 has clear evidence of efficacy and a favorable → Read More
Sage Therapeutics: Fooling Some Of The People All Of The Time
SAGE commands a $3.3B market cap based on its experimental drug SAGE-547. Data from its phase 1/2 trial in SRSE shows that SAGE-547 is undifferentiated relative → Read More
Ocera Therapeutics: When A Drug Fails, But Actually Works
OCRX lost 70% of its market cap after near miss in phase 2b trial of OCR-002 in hepatic encephalopathy Subsequent analysis shows OCR-002 to have meaningful phar → Read More